First clinical evidence that imaging with somatostatin receptor antagonists is feasible

Damian Wild, Melpomeni Fani, Martin Behe, Ingo Brink, Jean E.F. Rivier, Jean Claude Reubi, Helmut R. Maecke, Wolfgang A. Weber

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

164 Zitate (Scopus)

Abstract

Preclinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In this study, we evaluated whether imaging with sst antagonists was feasible in patients. Methods: Biodistribution and tumor uptake of the sst antagonist 111In-DOTA-pNO2-Phe- c(DCys-Tyr-DTrp-Lys-Thr-Cys)DTyrNH2 (111In-DOTA-BASS) were studied in 5 patients with metastatic thyroid carcinoma or neuroendocrine tumors. Findings were compared with 111In-pentetreotid ( 111In-DTPA-octreotide) scan. Results: No adverse effects of 111In-DOTA-BASS (20 μg) were observed. 111In-DOTA-BASS detected 25 of 28 lesions, whereas 111In-DTPA-octreotide detected only 17 of 28 lesions. In the same patient, 111In-DOTA-BASS showed higher tumor and lower renal uptake than 111In-DTPA-octreotide (3.5 ± 2.8 percentage injected activity [%IA] vs. 1.0 ± 0.99%IA and 1.5 ± 0.3%IA vs. 2.3 ± 0.7%IA) at 4 h after injection. Conclusion: Imaging of neuroendocrine tumors with sst antagonists is clinically feasible. The favorable human biodistribution data suggest that sst antagonists could significantly affect peptide receptor-mediated imaging and therapy.

OriginalspracheEnglisch
Seiten (von - bis)1412-1417
Seitenumfang6
FachzeitschriftJournal of Nuclear Medicine
Jahrgang52
Ausgabenummer9
DOIs
PublikationsstatusVeröffentlicht - 1 Sept. 2011
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „First clinical evidence that imaging with somatostatin receptor antagonists is feasible“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren